Myelodysplastic syndrome · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Midostaurin monotherapy Variant #01 | — | R 152 836 | 28d | — | — | ~2 | ~R 305 671 indirect | — |
Erlotinib monotherapy Variant #01 | — | R 13 907 | 28d | ~9.7 mo | ~8.8 mo | ~2 | ~R 27 814 PFS proxy · indirect | 30 |
Best supportive care Partial | — | — | — | — | ~8.5 mo | — | — | 3 |
3 of 3 regimens shown